Back to top
more

Precigen (PGEN)

(Delayed Data from NSDQ)

$3.12 USD

3.12
7,951,676

-0.07 (-2.19%)

Updated Oct 10, 2025 04:00 PM ET

After-Market: $3.10 -0.02 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

by Zacks Equity Research

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

Zacks Equity Research

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

by Zacks Equity Research

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

Zacks Equity Research

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precigen (PGEN) delivered earnings and revenue surprises of 33.33% and 2.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of -14.29% and 6.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

by Zacks Equity Research

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

Zacks Equity Research

Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precigen (PGEN) delivered earnings and revenue surprises of -12.50% and 13.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alvotech (ALVO) delivered earnings and revenue surprises of 226.67% and 5.63%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -38.10% and 87.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MaxCyte (MXCT) delivered earnings and revenue surprises of 15.38% and 8.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -6.72% and 0.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 43.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 89.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 9.38% and 462%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insulet (PODD) Q2 Earnings Miss Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of -3.51% and 5.48%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline

by Zacks Equity Research

Precigen (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Techne (TECH) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of -3.92% and 0.65%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vericel (VCEL) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy Precigen, Inc. (PGEN) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 34.29% and 108.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 13.64% and 45.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Paratek (PRTK) delivered earnings and revenue surprises of 7.89% and 1.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Heska (HSKA) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Heska (HSKA) delivered earnings and revenue surprises of -46.88% and 7.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?